SCHEMBL275658

SCHEMBL275658

CC(C)(C)OC(=O)N1C(=O)/C(=C\c2cc(F)cc(Cl)c2)c2ccc(Cl)cc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.35
MAPT P10636 1/20 0.35
SNCA P37840 1/20 0.35
PPARG P37231 1/20 0.35
CYP3A4 P08684 2/20 0.34
CYP3A5 P20815 2/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
PIM1 P11309 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRA6 Q16445 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL275659 1.00 APP (0.35) APPMAPTSNCAPPARGCYP3A4
SCHEMBL279165 0.90 PPARG (0.45) APPMAPTSNCAPPARGMEN1
SCHEMBL275607 0.90 PPARG (0.45) APPMAPTSNCAPPARGMEN1
SCHEMBL275608 0.90 PPARG (0.45) APPMAPTSNCAPPARGMEN1
SCHEMBL279452 0.87 APP (0.37) APPMAPTSNCAPPARGCYP3A4
SCHEMBL277025 0.86 MDM4 (0.43) APPMAPTSNCAPPARGMEN1
SCHEMBL274462 0.86 MDM4 (0.43) APPMAPTSNCAPPARGMEN1
SCHEMBL699531 0.86 MAPT (0.43) APPMAPTSNCAPPARGMEN1
SCHEMBL274463 0.86 MDM4 (0.43) APPMAPTSNCAPPARGMEN1
SCHEMBL279181 0.85 AMY1A (0.37) APPMAPTPPARGCYP3A4CYP3A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT APP 4745/4885MAPT 4062/4885SNCA 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.